Clinical review report: Tapentadol hydrochloride extended-release tablet (Nucynta extended-release) (Paladin labs inc.)
The objective of this review is to perform a systematic review of the beneficial and harmful effects of tapentadol hydrochloride extended-release tablets (Nucynta Extended-Release) 100 mg to 250 mg twice a day for the management of pain severe enough to require daily, continuous, long-term opioid tr...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, October 2018
|
Edition: | Final |
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this review is to perform a systematic review of the beneficial and harmful effects of tapentadol hydrochloride extended-release tablets (Nucynta Extended-Release) 100 mg to 250 mg twice a day for the management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid responsive; and for which alternative treatment options are inadequate. Nucynta Extended-Release is not indicated as an as-needed analgesic |
---|---|
Item Description: | "Indication: Management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid responsive; and for which alternative treatment options are inadequate. Tapentadol extended-release tablet is not indicated as an as-needed (prn) analgesic." |
Physical Description: | 1 PDF file (161 pages) illustrations |